Editor—Kahn emphasises that the results of the BiDil trial do not show that black African-Americans are biologically different from white Americans. Although he makes this point by contrasting it with a partial quotation from our editorial, his emphasis is very close to the tenor of our argument as summarised in the closing sentence: “A historical perspective is likely to be helpful—claims of a biological basis to racial or ethnic variations in health and disease, including therapeutics, have proved to be overstated.”
Differences, if any, between ethnic groups may be attributable to non-genetic factors, although genetic differences cannot be ruled out. Kahn's view is that the attention that BiDil has drawn to biological differences between populations is the major popular misreading of BiDil.1 The trialists data placed a great deal of emphasis on physiological particularities of black Americans,2 and if Kahn's viewpoint is correct then the popular misreading arises from a scientific one. There is great interest in ethnic variations in drug response (described as ethno-pharmacology, not to be confused with the discipline of the same name studying the therapeutic properties of traditional plants and remedies). Scholars in the field of race and ethnicity should follow this development. If genetic factors are found to be important in causing variations in drug response between populations then the concepts of race and ethnicity will need redefinition.
Kahn points to the commercial interests at stake. We are not in a position to comment, although we are impressed by the depth of his argument.1 The trialists ought to answer directly.2 Yogendra also points to the incentives of the marketplace.3 We were amused and educated by Hughes' quotation from Paracelsus showing that this debate was alive about 500 years ago.4
Competing interests: RSB was an invited speaker at the 8th world congress on clinical pharmacology and therapeutics, giving a presentation on concepts of ethnicity and race, and his expenses were met by both the congress and the James Lance GlaxoSmithKline Medicines Research Unit in Sydney.
References
- 1.Kahn J. How a drug becomes “ethnic”: law, commerce, and the production of racial categories in medicine. Yale J Health Policy Law Ethics 2004;4: 1-46. [PubMed] [Google Scholar]
- 2.Taylor AL, Ziesche S, Yancy C, Carson P, D'Agostino R, Ferdinand K, et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 2004;351: 2049-57. [DOI] [PubMed] [Google Scholar]
- 3.Yogendra S. Statistics and incentives [electronic response to Pharmacogenetics and ethnically targeted therapies]. bmj.com 2005. http://bmj.bmjjournals.com/cgi/eletters/330/7499/1036#106031 (accessed 16 Jun 2005).
- 4.Hughes I. Nothing new under the sun. [electronic response to Pharmacogenetics and ethnically targeted therapies]. bmj.com 2005. http://bmj.bmjjournals.com/cgi/eletters/330/7499/1036#106289 (accessed 16 Jun 2005).
